Evidence map›Paper›PMID 33046907›Full record

ArticleNature structural & molecular biology2020

Regulation of ALT-associated homology-directed repair by polyADP-ribosylation.

Song My Hoang, Nicole Kaminski, Ragini Bhargava, Jonathan Barroso-González, Michelle L Lynskey, Laura García-Expósito, Justin L Roncaioli, Anne R Wondisford, Callen T Wallace, Simon C Watkins and 12 more

Open access · greenAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 3 countries.

Song My HoangDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Nicole KaminskiDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Ragini BhargavaDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Jonathan Barroso-GonzálezDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Michelle L LynskeyDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Laura García-ExpósitoDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Justin L RoncaioliDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Anne R WondisfordDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Callen T WallaceDepartment of Cell Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-6852-4976
Simon C WatkinsDepartment of Cell Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-4092-1552
Dominic I JamesDrug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, Macclesfield, UK.
Ian D WaddellDrug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, Macclesfield, UK.
Donald OgilvieDrug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, Macclesfield, UK.
Kate M SmithDrug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, Macclesfield, UK.
Felipe da Veiga LeprevostDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-8228-5374
Dattatreya MellacharevuDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0001-8221-7673
Alexey I NesvizhskiiDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-2806-7819
Jianfeng LiDepartment of Pharmacology and the Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Dominique Ray-GalletInstitut Curie, PSL Research University, CNRS, Sorbonne Université, Nuclear Dynamics Unit, Equipe Labellisée, Ligue contre le Cancer, Paris, France.
Robert W SobolDepartment of Pharmacology and the Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.ORCID http://orcid.org/0000-0001-7385-3563
Genevieve AlmouzniInstitut Curie, PSL Research University, CNRS, Sorbonne Université, Nuclear Dynamics Unit, Equipe Labellisée, Ligue contre le Cancer, Paris, France.ORCID http://orcid.org/0000-0001-5570-0723
Roderick J O'SullivanDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. osullivanr@upmc.edu.ORCID http://orcid.org/0000-0002-0289-0911
UPMC Hillman Cancer Center · USUniversity of Manchester · GBUniversity of Michigan · USCentre National de la Recherche Scientifique · FRUSA Mitchell Cancer Institute · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
TRAINING PROGRAM FOR MD/PHD STUDENTST32GM008208 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STEINMAN, RICHARD A · 1987 to 2021
$15.4M
A Systems Approach to Mapping the DNA Damage ResponseR01ES014811 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2005 to 2021
$8.6M
COMPUTATIONAL TOOLS FOR MASS SPECTROMETRY-BASED INTERACTOME DATAR01GM094231 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 2010 to 2026
$5.4M
University of Michigan Proteogenomics Data Analysis CenterU24CA210967 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M, DHANASEKARAN, SARAVANA M · 2016 to 2020
$4.1M
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolismR01CA207209 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Roderick O'Sullivan · 2016 to 2026
$3.6M
Novel approaches to enhance tumor cell cytotoxicity of alkylating agentsR01CA148629 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SOBOL, ROBERT W · 2010 to 2021
$3.4M
PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIENCEST32GM008424 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PAGANO, PATRICK J · 1994 to 2019
$3.4M
Request for a Nikon A1 confocal microscopeS10OD019973 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WATKINS, SIMON C · 2015 to 2015
$358k
Cancer Research UK 17098Cancer Research UK C480/A11411Cancer Research UK C5759/A17098NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA148629NCI NIH HHS R01 CA207209NCI NIH HHS U24 CA210967NIEHS NIH HHS R01 ES014811NIGMS NIH HHS R01 GM094231NIGMS NIH HHS T32 GM008208NIGMS NIH HHS T32 GM008424NIH HHS S10 OD019973
6 · The paper itself

Abstract

The synthesis of poly(ADP-ribose) (PAR) reconfigures the local chromatin environment and recruits DNA-repair complexes to damaged chromatin. PAR degradation by poly(ADP-ribose) glycohydrolase (PARG) is essential for progression and completion of DNA repair. Here, we show that inhibition of PARG disrupts homology-directed repair (HDR) mechanisms that underpin alternative lengthening of telomeres (ALT). Proteomic analyses uncover a new role for poly(ADP-ribosyl)ation (PARylation) in regulating the chromatin-assembly factor HIRA in ALT cancer cells. We show that HIRA is enriched at telomeres during the G2 phase and is required for histone H3.3 deposition and telomere DNA synthesis. Depletion of HIRA elicits systemic death of ALT cancer cells that is mitigated by re-expression of ATRX, a protein that is frequently inactivated in ALT tumors. We propose that PARylation enables HIRA to fulfill its essential role in the adaptive response to ATRX deficiency that pervades ALT cancers.

Indexed as

Gene Expression Regulation, NeoplasticProtein Processing, Post-TranslationalRecombinational DNA RepairCell Cycle ProteinsCell Line, TumorChromatinDNA DamageDNA, NeoplasmEpithelial CellsG2 PhaseGlycoside HydrolasesHeLa CellsHistone ChaperonesHistonesHumansPoly Adenosine Diphosphate RiboseATRX protein, humanCell Cycle ProteinsChromatinDNA, NeoplasmGlycoside HydrolasesHIRA protein, humanHistone ChaperonesHistonesPoly Adenosine Diphosphate Ribosepoly ADP-ribose glycohydrolasePoly(ADP-ribose) PolymerasesRNA, Small InterferingTranscription FactorsX-linked Nuclear Protein

Identifiers

PMID33046907
PMCPMC7809635
OpenAlexW3092294216

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.